SCHEMBL17386181

SCHEMBL17386181

COC(=O)c1ccc2c(c1)-c1c(C)cc(OC)cc1CCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
ALDH1A1 P00352 4/20 0.42
CYP2C9 P11712 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 4/20 0.40
ATM Q13315 3/20 0.40
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NPC1 O15118 3/20 0.40
POLB P06746 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17386350 0.95 MAPT (0.44) BRD4CA1CA2ALDH1A1CYP2C9
SCHEMBL17429653 0.87 TDP1 (0.41) BRD4CA1CA2ALDH1A1CYP2C9
SCHEMBL17386058 0.86 CA12 (0.41) BRD4CA1CA2ALDH1A1NPSR1
SCHEMBL17386086 0.84 FFAR1 (0.43) BRD4ALDH1A1RAB9AATMMAPT
SCHEMBL17418097 0.84 FFAR1 (0.41) BRD4CYP2C9ATMMAPTKDM4E
SCHEMBL17399991 0.83 BRD4 (0.38) BRD4ALDH1A1NPSR1ATMMAPK14
SCHEMBL17418007 0.82 TSHR (0.45) BRD4CA1CA2ALDH1A1CYP2C9
SCHEMBL17417997 0.82 BRD4 (0.37) BRD4ALDH1A1NPSR1ATMMAPK14
SCHEMBL17400108 0.82 ATM (0.39) BRD4ALDH1A1CYP2C9TSHRRAB9A
SCHEMBL17429665 0.82 TDP1 (0.44) BRD4CA1CA2ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2963027-B1 TRICYCLIC COMPOUND AND USE THEREOF TIUMBIO CO LTD (KR) 2018-12-26 EP disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-9643946-B2 Tricyclic compound and use thereof SK CHEMICALS CO., LTD. (KR) 2017-05-09 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF SK CHEMICALS CO., LTD. (KR) 2016-01-14 US disclosed
EP-2963027-A1 TRICYCLIC COMPOUND AND USE THEREOF SK Chemicals Co., Ltd. (KR) 2016-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009677-A1 TRICYCLIC COMPOUND AND USE THEREOF GPR65, GPR119, GPR35 BRD4 1490/4885CA1 2727/4885CA2 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.